Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wide-ranging ramifications of China’s new price regulation

This article was originally published in SRA

Executive Summary

Newly introduced controls on the retail prices of basic drugs sold in China will have broad implications for existing sales, distribution, retail and supply arrangements, say lawyers at an Australian law firm familiar with the Chinese pharmaceutical market. The lawyers, from Allens Arthur Robinson, which has offices in China, advise that the commercial basis and contractual terms for such arrangements should be carefully reviewed1.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS114817

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel